Sunitinib-Associated Hypertension and Neutropenia as Efficacy Biomarkers in Metastatic Renal Cell Carcinoma Patients

British Journal of Cancer - United Kingdom
doi 10.1038/bjc.2015.368
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Hypertension as Predictor of Sunitinib Treatment Outcome in Metastatic Renal Cell Carcinoma

Acta Oncologica
Nuclear MedicineRadiologyHematologyOncologyMedicineImaging
2011English

Angiotensin Inhibitors as Treatment of Sunitinib/Pazopanib-Induced Hypertension in Metastatic Renal Cell Carcinoma

Clinical Genitourinary Cancer
OncologyUrology
2017English

Sunitinib in the Treatment of Metastatic Renal Cell Carcinoma

Therapeutic Advances in Urology
Urology
2016English

Phase I Trial of Sunitinib and Temsirolimus in Metastatic Renal Cell Carcinoma

Clinical Genitourinary Cancer
OncologyUrology
2015English

Safety and Efficacy of Sunitinib for Advanced Non-Clear Cell Renal Cell Carcinoma

Asia-Pacific Journal of Clinical Oncology
MedicineOncology
2015English

Long-Term Response to Sunitinib Therapy for Metastatic Renal Cell Carcinoma

Clinical Genitourinary Cancer
OncologyUrology
2013English

Mp16-01 Clinical Implications of Sunitinib and N-Desethyl-Sunitinib Plasma Concentrations for Treatment Outcome in Metastatic Renal Cell Carcinoma Patients

Journal of Urology
Urology
2017English

Sunitinib Causes Macrocytosis in Patients With Advanced Renal Cell Carcinoma

Current Oncology
Oncology
2010English

Efficacy and Safety of Sunitinib Alternate Day Regimen in Patients With Metastatic Renal Cell Carcinoma in Japan: Comparison With Standard 4/2 Schedule

Asia-Pacific Journal of Clinical Oncology
MedicineOncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy